{"preliminary_commentary":{"by_channel":{"x_thread":12,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02834013\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab","ipilimumab"],["nivolumab"]],"indication":"rare tumors","name":"SWOG S1609","nct_id":"NCT02834013","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=swog-s1609-nct02834013. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who complete 17 cycles (2 years) of therapy, may continue receiving the same treatment with nivolumab and ipilimumab, or receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) per physician discretion in the absence of disease progression or unacceptable toxicity. Patients who stop treatment prior to the completion of 17 cycles of therapy may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and on study. Patients also undergo MRI or CT throughout the trial. Additionally, patients undergo blood sample collection throughout the trial.","label":"Arm I (nivolumab, ipilimumab)","type":"EXPERIMENTAL"},{"description":"Patients receive nivolumab IV over 30 minutes on days 1, 15 and 29. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. After 17 cycles (2 years) of therapy, patients may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and on study. Patients also undergo MRI or CT throughout the trial. Additionally, patients undergo blood sample collection throughout the trial.","label":"Arm II (nivolumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"conditions":["Acinar Cell Carcinoma","Adenoid Cystic Carcinoma","Adrenal Cortical Carcinoma","Adrenal Gland Pheochromocytoma","Anal Canal Neuroendocrine Carcinoma","Anal Canal Undifferentiated Carcinoma","Angiosarcoma","Apocrine Neoplasm","Appendix Mucinous Adenocarcinoma","Bartholin Gland Transitional Cell Carcinoma","Basal Cell Carcinoma","Bladder Adenocarcinoma","Breast Metaplastic Carcinoma","Cervical Adenocarcinoma","Cholangiocarcinoma","Chordoma","Colorectal Squamous Cell Carcinoma","Desmoid Fibromatosis","Endometrial Transitional Cell Carcinoma","Endometrioid Adenocarcinoma","Esophageal Neuroendocrine Carcinoma","Esophageal Undifferentiated Carcinoma","Extrahepatic Bile Duct Carcinoma","Extramammary Paget Disease","Fallopian Tube Adenocarcinoma","Fallopian Tube Transitional Cell Carcinoma","Fibromyxoid Tumor","Gallbladder Carcinoma","Gastric Neuroendocrine Carcinoma","Gastric Squamous Cell Carcinoma","Gastric Undifferentiated Carcinoma","Gastrointestinal Stromal Tumor","Gestational Trophoblastic Tumor","Giant Cell Carcinoma","Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type","Intestinal Neuroendocrine Carcinoma","Intrahepatic Cholangiocarcinoma","Lung Neuroendocrine Tumor","Lung Sarcomatoid Carcinoma","Major Salivary Gland Carcinoma","Malignant Neoplasm of Unknown Primary","Malignant Odontogenic Neoplasm","Malignant Peripheral Nerve Sheath Tumor","Malignant Solid Neoplasm","Malignant Testicular Sex Cord-Stromal Tumor","Metastatic Pituitary Neuroendocrine Tumor","Minimally Invasive Lung Adenocarcinoma","Mixed Mesodermal (Mullerian) Tumor","Mucinous Adenocarcinoma","Mucinous Cystadenocarcinoma","Nasal Cavity Adenocarcinoma","Nasal Cavity Carcinoma","Nasopharyngeal Carcinoma","Nasopharyngeal Low Grade Papillary Adenocarcinoma","Nasopharyngeal Undifferentiated Carcinoma","Oral Cavity Carcinoma","Oropharyngeal Undifferentiated Carcinoma","Ovarian Adenocarcinoma","Ovarian Germ Cell Tumor","Ovarian Mucinous Adenocarcinoma","Ovarian Squamous Cell Carcinoma","Ovarian Transitional Cell Carcinoma","Pancreatic Acinar Cell Carcinoma","Pancreatic Neuroendocrine Carcinoma","Paraganglioma","Paranasal Sinus Adenocarcinoma","Paranasal Sinus Carcinoma","Parathyroid Gland Carcinoma","PEComa","Penile Squamous Cell Carcinoma","Peritoneal Mesothelial Neoplasm","Placental Choriocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Pseudomyxoma Peritonei","Rare Disorder","Scrotal Squamous Cell Carcinoma","Seminal Vesicle Adenocarcinoma","Seminoma","Serous Cystadenocarcinoma","Small Intestinal Adenocarcinoma","Small Intestinal Squamous Cell Carcinoma","Spindle Cell Neoplasm","Teratoma With Somatic-Type Malignancy","Testicular Non-Seminomatous Germ Cell Tumor","Thyroid Gland Carcinoma","Tracheal Carcinoma","Transitional Cell Carcinoma","Ureter Adenocarcinoma","Ureter Squamous Cell Carcinoma","Urethral Adenocarcinoma","Urethral Squamous Cell Carcinoma","Vaginal Adenocarcinoma","Vaginal Squamous Cell Carcinoma, Not Otherwise Specified","Vulvar Carcinoma"],"enrollment":{"count":798,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Echocardiography Test","otherNames":["EC","Echocardiography"],"type":"PROCEDURE"},{"name":"Ipilimumab","otherNames":["Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","BMS 734016","BMS-734016","BMS734016","Ipilimumab Biosimilar CS1002","MDX 010","MDX-010","MDX-CTLA4","MDX010","Yervoy"],"type":"BIOLOGICAL"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Nivolumab","otherNames":["ABP 206","BCD-263","BMS 936558","BMS-936558","BMS936558","CMAB819","MDX 1106","MDX-1106","MDX1106","NIVO","Nivolumab Biosimilar ABP 206","Nivolumab Biosimilar BCD-263","Nivolumab Biosimilar CMAB819","ONO 4538","ONO-4538","ONO4538","Opdivo"],"type":"BIOLOGICAL"}],"last_update":"2026-06-17","lead_sponsor":"National Cancer Institute (NCI)","official_title":"DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-05-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall response rate (ORR)","timeFrame":"Up to 10 years"}],"references":[{"citation":"Chae YK, Sun R, Patel SP, Giles F, Ohr JP, Worden FP, Suga JM, Naing A, Cohen EE, Wallace J, Kang HS, Fenton S, Chung LI, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Othus M, Blanke CD, Kurzrock R. A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort. Ther Adv Med Oncol. 2026 Jul 23;18:17588359261451739. doi: 10.1177/17588359261451739. eCollection 2026.","pmid":"42499790","type":"DERIVED"},{"citation":"Chae YK, Czeskleba J, Patel SP, Mentor A, Robinson W, Jones NL, Rampurwala M, Naing A, Beck JM, Moloney-Lineen C, Chung LI, McLeod CM, Chen HX, Sharon E, Threlkel S, Othus M, Ryan CW, Blanke CD, Kurzrock R. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results. J Gynecol Oncol. 2026 Mar 25. doi: 10.3802/jgo.2026.37.e92. Online ahead of print.","pmid":"41995270","type":"DERIVED"},{"citation":"Swiecicki PL, Othus M, Patel SP, Kwang-Chae Y, Kurzrock R. Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609). Cancer. 2026 Apr 1;132(7):e70374. doi: 10.1002/cncr.70374.","pmid":"41892875","type":"DERIVED"},{"citation":"Chae YK, Othus M, Patel SP, Backes FJ, O'Malley DM, Cristea M, Naing A, Kurnit K, Eskander RN, T Goodrich S, Robinson WR, Scalici J, Chan J, Ali-Ahmad H, Hays J, McCormick C, Kim EJ, Sueblinvong T, Ahmed A, Siedel J, Thomes Pepin J, Bottsford-Miller JN, Fagbemi SO, Jaslowski AJ, Kim HS, Chung LI, Moloney-Lineen C, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. J Immunother Cancer. 2026 Feb 11;14(2):e012805. doi: 10.1136/jitc-2025-012805.","pmid":"41672597","type":"DERIVED"},{"citation":"Patel SP, Fisher J, Chae YK, Soto LS, Kasi A, Konda B, Walshauser M, Parra E, Zhang J, Duault C, Gonzalez-Kozlova E, Manyam G, Zhang J, Chen H, Duose DY, Laberiano Fernandez C, Luthra R, Al-Atrash G, Kim-Schulze S, Maecker HT, Wistuba II, Gnjatic S, Lee JJ, Zhang J, Magner CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke C, Haymaker CL, Kurzrock R. Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort. J Immunother Cancer. 2025 Jun 30;13(6):e011760. doi: 10.1136/jitc-2025-011760.","pmid":"40588371","type":"DERIVED"},{"citation":"Chae YK, Othus M, Patel SP, Aljumaily R, Win KZ, Pejovic T, Thomas SS, Robinson WR 3rd, Kim HS, Chung LI, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Cancer Commun (Lond). 2025 Aug;45(8):976-986. doi: 10.1002/cac2.70020. Epub 2025 May 22.","pmid":"40402690","type":"DERIVED"},{"citation":"Patel SP, Cano-Linson E, Chae YK, Schokrpur S, Lao CD, Powers BC, Victor AI, Onitilo AA, Shin S, Takebe N, Threlkel S, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke CD, Kurzrock R. Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma. NPJ Precis Oncol. 2025 Jan 24;9(1):24. doi: 10.1038/s41698-024-00798-1.","pmid":"39856213","type":"DERIVED"},{"citation":"Chae YK, Othus M, Patel SP, Gerber DE, Tanvetyanon T, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma). Ther Adv Med Oncol. 2024 Nov 22;16:17588359241293401. doi: 10.1177/17588359241293401. eCollection 2024.","pmid":"39583952","type":"DERIVED"},{"citation":"Chae YK, Othus M, Patel SP, Wilkinson KJ, Whitman-Purves EM, Lea J, Schallenkamp JM, Adra N, Appleman LJ, Alden M, Thomes Pepin J, Ellerton JA, Poklepovic A, Walter A, Rampurwala MM, Robinson WR, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024 Dec 16;30(24):5593-5600. doi: 10.1158/1078-0432.CCR-24-0606.","pmid":"39417692","type":"DERIVED"},{"citation":"Chae YK, Othus M, Patel S, Powers B, Hsueh CT, Govindarajan R, Bucur S, Kim HS, Chung LI, McLeod C, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke C, Kurzrock R. Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors. J Immunother Cancer. 2024 Sep 28;12(9):e009128. doi: 10.1136/jitc-2024-009128.","pmid":"39343510","type":"DERIVED"},{"citation":"Patel SP, Othus M, Chae YK, Huynh T, Tan B, Kuzel T, McLeod C, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke C, Kurzrock R. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort. J Immunother Cancer. 2024 Jul 27;12(7):e009074. doi: 10.1136/jitc-2024-009074.","pmid":"39067873","type":"DERIVED"},{"citation":"Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, Ferri WA Jr, George TJ, Sharon E, Ryan CW, Othus M, Lopez G, Blanke CD, Kurzrock R. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer. Cancer. 2024 Sep 1;130(17):2918-2927. doi: 10.1002/cncr.35243. Epub 2024 Feb 15.","pmid":"38358334","type":"DERIVED"},{"citation":"Othus M, Patel SP, Chae YK, Dietrich E, Streicher H, Sharon E, Kurzrock R. Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. J Natl Cancer Inst. 2024 May 8;116(5):673-680. doi: 10.1093/jnci/djae009.","pmid":"38243705","type":"DERIVED"},{"citation":"Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2022 Jan 15;28(2):271-278. doi: 10.1158/1078-0432.CCR-21-2182. Epub 2021 Oct 29.","pmid":"34716198","type":"DERIVED"},{"citation":"Wagner MJ, Othus M, Patel SP, Ryan C, Sangal A, Powers B, Budd GT, Victor AI, Hsueh CT, Chugh R, Nair S, Leu KM, Agulnik M, Sharon E, Mayerson E, Plets M, Blanke C, Streicher H, Chae YK, Kurzrock R. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021 Aug;9(8):e002990. doi: 10.1136/jitc-2021-002990.","pmid":"34380663","type":"DERIVED"},{"citation":"Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Plets M, Blanke CD, Kurzrock R. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer. 2021 Sep 1;127(17):3194-3201. doi: 10.1002/cncr.33591. Epub 2021 Apr 21.","pmid":"33882143","type":"DERIVED"},{"citation":"Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020.","pmid":"33362722","type":"DERIVED"},{"citation":"Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22.","pmid":"31969335","type":"DERIVED"}],"start_date":{"date":"2017-01-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","url":"https://clinicaltrials.gov/study/NCT02834013"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/swog-s1609-nct02834013"}